title: Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans.
abstract: BACKGROUND
  Multivariate assays (MVAs) for assisting clinical decisions are becoming commonly available, but due to complexity, are often considered a high-risk approach. A key concern is that uncertainty on the assay's final results is not well understood. This study focuses on developing a process to characterize error introduced in the MVA's results from the intrinsic error in the laboratory process: sample preparation and measurement of the contributing factors, such as gene expression.
  
  
  METHODS
  Using the PAM50 Breast Cancer Intrinsic Classifier, we show how to characterize error within an MVA, and how these errors may affect results reported to clinicians. First we estimated the error distribution for measured factors within the PAM50 assay by performing repeated measures on four archetypal samples representative of the major breast cancer tumor subtypes. Then, using the error distributions and the original archetypal sample data, we used Monte Carlo simulations to generate a sufficient number of simulated samples. The effect of these errors on the PAM50 tumor subtype classification was estimated by measuring subtype reproducibility after classifying all simulated samples. Subtype reproducibility was measured as the percentage of simulated samples classified identically to the parent sample. The simulation was thereafter repeated on a large, independent data set of samples from the GEICAM 9906 clinical trial. Simulated samples from the GEICAM sample set were used to explore a more realistic scenario where, unlike archetypal samples, many samples are not easily classified.
  
  
  RESULTS
  All simulated samples derived from the archetypal samples were classified identically to the parent sample. Subtypes for simulated samples from the GEICAM set were also highly reproducible, but there were a non-negligible number of samples that exhibit significant variability in their classification.
  
  
  CONCLUSIONS
  We have developed a general methodology to estimate the effects of intrinsic errors within MVAs. We have applied the method to the PAM50 assay, showing that the PAM50 results are resilient to intrinsic errors within the assay, but also finding that in non-archetypal samples, experimental errors can lead to quite different classification of a tumor. Finally we propose a way to provide the uncertainty information in a usable way for clinicians.
authors.affiliation: Department of Biomedical Informatics, University of Utah, Salt Lake City, UT, USA. Julio.Facelli@utah.edu.
authors.forename: Mark Tw
authors.initials: MT
authors.lastname: Ebbert
authors.forename: Roy Rl
authors.initials: RR
authors.lastname: Bastien
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Boucher
authors.forename: Miguel
authors.initials: M
authors.lastname: Martín
authors.forename: Eva
authors.initials: E
authors.lastname: Carrasco
authors.forename: Rosalía
authors.initials: R
authors.lastname: Caballero
authors.forename: Inge J
authors.initials: IJ
authors.lastname: Stijleman
authors.forename: Philip S
authors.initials: PS
authors.lastname: Bernard
authors.forename: Julio C
authors.initials: JC
authors.lastname: Facelli